×
About 3,340 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  1,138 results

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02688140

Aug 5th, 2022 - Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification APL is designated as"M3 leukemia" and assigned to the...

Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad...
https://doi.org/10.1080/10428194.2022.2105328
Leukemia & Lymphoma; Testi AM, Al-Jadiry MF et. al.

Aug 2nd, 2022 - Modern treatments have dramatically improved the prognosis of childhood acute promyelocytic leukemia (APL). This progress has not yielded equivalent benefit in developing countries, where biological studies and supportive cares are insufficient an...

A novel RARA-SNX15 fusion in PML-RARA-positive acute promyelocytic leukemia with t(11;1...
https://doi.org/10.1007/s12185-022-03421-w
International Journal of Hematology; Hirade K, Kusumoto S et. al.

Jul 20th, 2022 - Acute promyelocytic leukemia (APL) is characterized by a series of retinoic acid receptor (RAR) fusion genes that lead to the dysregulation of RAR signaling and onset of APL. PML-RARA is the most common fusion generated from t(15;17)(q24;q21). In ...

Early mortality continues to be a barrier to excellent survival in childhood acute prom...
https://doi.org/10.1080/08880018.2022.2082610
Pediatric Hematology and Oncology; Roy PS, Munikoty V et. al.

Jul 19th, 2022 - Data on childhood acute promyelocytic leukemia (APL) from low-and middle-income countries is limited. Early mortality is a concern and often not highlighted in clinical trials. The retrospective study was conducted on patients (≤12 years) with APL...

Chronic Lymphocytic Leukemia (CLL) Differential Diagnoses
https://emedicine.medscape.com/article/199313-differential

Jul 15th, 2022 - Diagnostic Considerations Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease; SLL is diagnosed when the disease is mainly nodal, and CLL is diagnosed when the disease is seen in...

see more →

Guidelines  2 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  14 results see all →

Clinicaltrials.gov  82 results

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02688140

Aug 5th, 2022 - Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification APL is designated as"M3 leukemia" and assigned to the...

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT04996030

Jul 14th, 2022 - This study includes 4 parts. In the first part, enrolled participants will receive a single dose of IV ATO, followed a week later by a single dose of SY-2101, SY-2101 will be administered to participants in either a fed or a fasted condition. A we...

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01409161

May 10th, 2022 - PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in patients with low-risk untreated acute promyelocytic leukemia (APL). II. Ass...

A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02200978

May 10th, 2022 - OBJECTIVES: Determine the safety and efficacy of "ATO/RIF + ATRA + less intensive chemotherapy" protocol in children with acute promyelocytic leukemia (APL). Compare the safety,efficacy and treatment cost of "RIF + ATRA + less intensive chemother...

Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT01518556

Apr 15th, 2022 - Up to nowadays, a standard induction therapy for acute myeloid leukemia(AML) has consisted of cytarabine 100-200 mg per square meter of body surface area(BSA) per day continuous infusion for 7 days with idarubicin 12 mg per square meter or daunoru...

see more →

News  100 results

FDA Grants Fast Track Status to PRGN-3006 for Relapsed/Refractory AML
https://www.onclive.com/view/fda-grants-fast-track-status-to-prgn-3006-for-relapsed-refractory-aml

May 2nd, 2022 - The FDA has granted a fast track designation to the multigenic autologous CAR T-cell therapy PRGN-3006 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia (AML), according to an announcement fro...

Acute Promyelocytic Leukemia: A Subset of Acute Myeloid Leukemia
https://www.medscape.com/viewarticle/964529

Apr 14th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz, and welcome to Medscape InDiscussion. Today, we're going to be talking about acute myeloid leukemia (AML) and specifically a subtype of AML, ca...

Good-Risk Acute Myeloid Leukemia
https://www.medscape.com/viewarticle/964531

Apr 14th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York Ci...

Precision medicine: A new approach to AML, other blood cancers
https://www.mdedge.com/hematology-oncology/article/249816/aml
Caleb Rans, PharmD

Dec 12th, 2021 - The emergence of precision medicine has ushered in a groundbreaking era for the treatment of myeloid malignancies, with the ability to integrate individual molecular data into patient care. Over the past decade, insights from research focusing on.

'Shocking' Lack of Lifesaving Leukemia Drug at US Hospitals
https://www.medscape.com/viewarticle/964213

Dec 6th, 2021 - A drug crucial for the emergency management of acute promyelocytic leukemia (APL) simply isn't stocked by many US hospitals, according to a recent report in the Journal of the National Comprehensive Cancer Network. The drug — all-trans retinoic ac...

see more →